Identification of Antibodies Against PLA2R Peptides in Membranous Nephropathy

61.9% of patients with PLA2R-associated membranous nephropathy who tested negative for conventional circulating anti-PLA2R antibodies reacted to at least one linear PLA2R peptide. The dataset contains ELISA measurements of IgG antibodies against 123 synthetic peptides from 42 biopsy-proven patients, authored by Miao Wang and last updated in May 2026. Three peptides—CysR-11, CTLD7-1, and CTLD7-2—showed the highest recognition frequencies and may serve as exploratory candidate biomarkers.

Use Cases

• Train diagnostic models based on antibody reactivity patterns to linear PLA2R peptides.
• Identify candidate peptide biomarkers for PLA2R-associated membranous nephropathy based on recognition frequencies.
• Compare serological profiles between anti-PLA2R-negative and anti-PLA2R-positive patient cohorts.
• Validate the specificity of peptide reactivity against other glomerular diseases mentioned in the description.

Strengths

• Data is derived from 42 biopsy-proven PLA2R-associated MN patients, providing a clinically confirmed cohort.
• Antibody reactivity was tested against a panel of 123 synthesized linear peptides, covering ten domains of the PLA2R extracellular region.
• Specificity was tested against control groups including patients with minimal change disease, focal segmental glomerulosclerosis, IgA nephropathy, and other MN types.

Limitations

• The dataset is small in scale at 78.8 KB, suggesting limited sample size.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale machine learning.

Provenance

Source

figshare

Collection Method

ELISA measurements of circulating IgG antibodies against synthesized peptides.

Freshness

Last updated 2026-05-28 06:17:13; freshness should be verified.